Novartis Announces Three Major Partnership Deals Worth Over $5 Billion Combined

Novartis has entered into three separate research and licensing partnerships with a combined potential value exceeding $5 billion to develop therapies in oncology, complex diseases, and cardiovascular areas. The deals involve Antares Therapeutics, Orionis Biosciences, and Unnatural Products, each leveraging distinct proprietary platforms.

Antares Therapeutics will receive up to $1.9 billion in upfront and milestone payments to develop therapies targeting historically undruggable oncology targets. The company will receive $105 million upfront and tiered royalties on global net sales that could reach the low double-digit percentage range. Antares will oversee research activities using its proprietary discovery platform, which includes screening libraries, chemical proteomics, structure-driven computational chemistry, and a machine-learning suite, until Novartis exercises its options.

Orionis Biosciences announced a multi-year partnership with Novartis valued at up to $1.4 billion to explore and develop molecular glue drugs targeting complex therapeutic areas. Orionis will receive an initial payment of $40 million. The collaboration focuses on the Allo-Glue platform and AI-powered discovery engine to enhance profiling of ligases and targets, optimizing the development of molecular glues through mechanisms of induced proximity.

Unnatural Products has entered into a $1.8 billion agreement to develop oral peptide therapies for cardiovascular diseases. Unnatural Products could receive up to $100 million in upfront and pre-IND milestone payments, with additional potential earnings of $1.7 billion in milestone payments and royalties from sales. Novartis will oversee clinical trials, production, and commercialization, while Unnatural Products provides its AI-driven macrocycle platform.

Novartis has a market capitalization of approximately $318.3 billion and maintains a robust established medicines business across oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic areas. The company operates globally, with the United States contributing nearly one-third of its total revenue. In March, Novartis also agreed to acquire Excellergy Inc. for up to $2 billion and strengthened its breast cancer pipeline with the Synnovation Therapeutics deal worth $3 billion.